Clinical Trial Update: A Clinical Trial to Demonstrate the Efficacy and Safety of Cenestin 0.3 mg for the Treatment of Hot Flashes [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating Cenestin 0.3 mg for hot flashes has completed and aims to demonstrate its efficacy and safety.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hot Fl Ash Es

Drugs mentioned

• Cenestin 0.3 mg (conjugated estrogens)

Snippet

Sponsor: Duramed Research | Conditions: Hot Flashes | Phase 3 | Status: COMPLETED